Erbitux’s enjoyment over RSA effect, Viread’s explosive upturn

‘Erbitux,’ the Merck’s targeted therapy for metastatic colorectal cancer, has well enjoyed the effect of the risk-sharing system.

Moreover, ‘Viread,’ the Gilead’s hepatitis B treatment, has shown an incredible growth by more than double along with the extension of the health insurance benefit.

According to the analysis result of the ‘2015 EDI Prescription Product Status(Top 50)’ submitted b...